The primary outcome of the unblinded, randomized trial was the proportion of patients without recurrent Clostridium difficile infection 12 weeks after fecal transplant.
In a survey, 41.3% of respondents with inflammatory bowel disease (IBD) said treatment efficacy was the most important attribute for a biologic, and 53.9% preferred subcutaneous administration at home over IV administration in a clinic.
Progression was found to be significantly associated with increasing age, male sex, smoking, and increasing segment length, with a low degree of heterogeneity.
This month's quiz asks readers to determine the most appropriate follow-up for a 41-year-old woman who was diagnosed with gallstones after an ED visit 1 week ago.
The drug is the first FDA-approved biosimilar to treat breast or stomach cancer and the second FDA-approved biosimilar to treat cancer.